PaperTen-year neonatal hepatitis B vaccination program, the Netherlands, 1982–1992: protective efficacy and long-term immunogenicity
References (22)
- et al.
Anti-HBs levels in infants of hepatitis B carrier mothers after delayed active immunization with recombinant vaccine concomitant with DTP-Polio vaccine: Is there need for a second dose of HBlg?
Vaccine
(1994) - et al.
Failure of neonatal hepatitis B vaccination: The role of HBV DNA levels in hepatitis B carrier mothers and HLA antigens in neonates
Journal of Hepatology
(1994) - et al.
Prevention of hepatitis B virus carrier state in infants according to maternal serum levels of HBV DNA
Lancet
(1989) - et al.
Early predictor of the efficacy of immunoprophylaxis against perinatal hepatitis B transmission: analysis of prophylaxis failure
Vaccine
(1991) - et al.
Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine
Lancet
(1983) - et al.
Prevention of the HBsAg carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HBeAg by administration of hepatitis B vaccine and hepatitis B immunoglobulin
Lancet
(1984) - et al.
Seven-year study of hepatitis B vaccine efficacy in infants from an endemic area (Senegal)
Lancet
(1986) - et al.
Vaccine-induced escape mutant of hepatitis B virus
Lancet
(1990) - et al.
Passive-active immunisation of neonates of HBsAg positive carrier mothers: preliminary observations
British Medical Journal
(1984) - et al.
Prevention of hepatitis B infection in newborns through mass screening and delayed vaccination of all infants of mothers with hepatitis B surface antigen
Pediatrics
(1989)
Prevention of maternal-infant hepatitis B virus transmission by immunization: The role of serum hepatitis B virus DNA
Hepatology
(1986)
Cited by (173)
Society for Maternal-Fetal Medicine Consult Series #69: Hepatitis B in pregnancy: updated guidelines
2024, American Journal of Obstetrics and GynecologyManagement of Viral Complications of Pregnancy: Pharmacotherapy to Reduce Vertical Transmission
2021, Obstetrics and Gynecology Clinics of North AmericaCitation Excerpt :This strategy is highly effective yet does not eliminate MTCT. Studies have demonstrated that the risk of failure of this passive-active immunization strategy is directly related to the presence of maternal e antigen (hepatitis B e antigen [HBeAg]) and to maternal viral load, with a viral load greater than 6 log10 copies/mL being the most important determinant of MTCT.45–51 Targeting women with high viral loads for antiviral treatment could further reduce MTCT of HBV.
Maternal HBeAg positivity and viremia associated with umbilical cord blood hepatitis B viremia
2019, Pediatrics and NeonatologyTreatment of Viral Infections During Pregnancy
2019, Clinics in PerinatologyHepatitis B Vaccines
2017, Plotkin's Vaccines
Copyright © 1997 Published by Elsevier Ltd.